Ozempic (semaglutide)

Novo Nordisk Ozempic semaglutide

Marketing

Novo accuses Lilly of running ‘false and misleading’ GLP-1 ads

The Danish drugmaker said the “false and misleading advertising is causing irreparable harm to Novo Nordisk and to the patients Lilly deceives.”

Nick Paul Taylor Jul 21, 2026 9:18am

Pause button

Dr. Reddy's temporarily pauses generic semaglutide supplies

Jul 9, 2026 8:48am

Mike Doustdar Novo Nordisk Novo Novo CEO

Novo Nordisk’s ‘optimistic’ CEO Doustdar sits down with Fierce

Jun 11, 2026 7:00am

Measuring tape on top of cash

GLP-1s oust oncology as top late-stage pipeline value driver

May 4, 2026 7:00am

Novo Nordisk

Rybelsus brand retired in US as ‘Ozempic pill’ takes the stage

May 1, 2026 8:00am

Novo Nordisk

Novo eyes adolescent diabetes approval for oral semaglutide

Apr 23, 2026 11:03am